With AiMIFY™ FDA clearance in 2024 and subsequent CE Mark in 2025, Bracco has taken another step forward in its shared mission of providing innovative artificial intelligence (AI)-based solutions that can improve diagnostic confidence and support radiologists and patients worldwide. AiMIFY leverages advanced AI technology to amplify the contrast enhancement of brain MRI scans — up to twice the level typically achieved with a labeled dose of gadolinium-based contrast agents (GBCAs). This provides radiologists with improved contrast information - particularly aiding in the visualization of small and poorly enhanced lesions, which can be critical for the early detection and assessment of certain conditions. AiMIFY is an exclusive collaboration between Bracco and Subtle Medical, Inc., a pioneering innovator in AI-powered image acquisition.